Omiflux Capsule is a combination medication containing Domperidone 10 mg and Omeprazole 20 mg, indicated for the treatment of gastrointestinal disorders characterized by acid reflux, heartburn, and delayed gastric emptying. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility by increasing the movement of the stomach and intestines, thereby facilitating gastric emptying and reducing symptoms such as nausea and vomiting. Omeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, leading to decreased acidity in the stomach. This dual-action formulation provides symptomatic relief in conditions like gastroesophageal reflux disease (GERD), dyspepsia, and peptic ulcer disease by addressing both acid suppression and motility enhancement. Omiflux Capsule should be administered orally, preferably before meals, as directed by a healthcare professional. Caution is advised in patients with known hypersensitivity to either component, liver impairment, or underlying cardiac conditions. Common adverse effects may include headache, dry mouth, abdominal discomfort, and, rarely, extrapyramidal symptoms due to Domperidone. Regular monitoring and adherence to prescribed dosage are essential to optimize therapeutic outcomes and minimize potential risks.